PMC:7464116 / 66147-68825 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

LitCovid-PD-UBERON

LitCovid-PD-MONDO

LitCovid-PD-CLO

LitCovid-PD-CHEBI

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T395","span":{"begin":0,"end":187},"obj":"Sentence"},{"id":"T396","span":{"begin":188,"end":495},"obj":"Sentence"},{"id":"T397","span":{"begin":496,"end":631},"obj":"Sentence"},{"id":"T398","span":{"begin":632,"end":697},"obj":"Sentence"},{"id":"T399","span":{"begin":698,"end":818},"obj":"Sentence"},{"id":"T400","span":{"begin":819,"end":924},"obj":"Sentence"},{"id":"T401","span":{"begin":925,"end":1015},"obj":"Sentence"},{"id":"T402","span":{"begin":1016,"end":1115},"obj":"Sentence"},{"id":"T403","span":{"begin":1116,"end":1218},"obj":"Sentence"},{"id":"T404","span":{"begin":1219,"end":1308},"obj":"Sentence"},{"id":"T405","span":{"begin":1309,"end":1408},"obj":"Sentence"},{"id":"T406","span":{"begin":1409,"end":1507},"obj":"Sentence"},{"id":"T407","span":{"begin":1508,"end":1819},"obj":"Sentence"},{"id":"T408","span":{"begin":1820,"end":1950},"obj":"Sentence"},{"id":"T409","span":{"begin":1951,"end":2210},"obj":"Sentence"},{"id":"T410","span":{"begin":2211,"end":2379},"obj":"Sentence"},{"id":"T411","span":{"begin":2380,"end":2452},"obj":"Sentence"},{"id":"T412","span":{"begin":2453,"end":2566},"obj":"Sentence"},{"id":"T413","span":{"begin":2567,"end":2678},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"However, kidney-transplant recipients appear to be at particularly high risk for critical COVID-19 illness because of both their chronic immunosuppression and coexisting conditions [130]. Recently, at Montefiore Medical Center, NY, 36 consecutive adult kidney-transplant recipients who were positive for COVID-19 were identified [131], and Columbia University Kidney transplant program enrolled 15 kidney transplant recipients who required hospitalization for confirmed COVID-19 infection [132]. Both reports described management, clinical course and outcomes of those patients living with a kidney transplant affected by COVID-19. Patients were predominantly men, and the median age was 55 years. The most common comorbidities were the following: hypertension, diabetes mellitus, history of smoking and heart disease. Almost all patients were receiving tacrolimus, prednisone and mycophenolate mofetil or mycophenolic acid. The patients reported symptom onset ranging from 1 day to nearly 3 weeks before admission. The most common initial symptom was fever, but also cough, dyspnea, malaise, diarrhea and myalgias. Over 50% of the patients had bilateral/multifocal opacities noted on initial chest x-ray radiographic. Laboratory findings were lymphopenia, thrombocytopenia, low CD3, CD4 and CD8 cell counts. As inflammatory markers, ferritin levels, C- reactive protein, procalcitonin and D-dimer were high. Patients who were in a stable condition without major respiratory symptoms were monitored at home. In another report, among 41 outpatient kidney transplant recipients with suspected or known COVID-19 infection, about one third required hospitalization by the end of their follow-up; there were no differences in demographics or medical comorbidities between those who were or were not admitted to the hospital. These patients therefore required close clinical monitoring to prevent their organ deterioration until symptoms’ resolution [133]. As reported by Montefiore Medical Center and Columbia University, almost half of the patients had AKI, although none had a kidney biopsy performed to determine the cause, and required intubation and mechanical ventilation between 0 and 9 days after admission. In particular, Columbia University’s report observed that 27% of their cases required intubation, a proportion that is similar for cases in New York City overall [132]. Among the patients who developed AKI, only 20% of patients required RRT. At a median follow-up of 21 days, the mortality rate was about 28% of the kidney-transplant recipients [131,132]. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin."}

LitCovid-PD-HP

LitCovid-PubTator

2_test

{"project":"2_test","denotations":[{"id":"32759645-32354634-58096253","span":{"begin":182,"end":185},"obj":"32354634"},{"id":"32759645-32317402-58096254","span":{"begin":490,"end":493},"obj":"32317402"},{"id":"32759645-31869307-58096255","span":{"begin":1945,"end":1948},"obj":"31869307"},{"id":"32759645-32317402-58096256","span":{"begin":2374,"end":2377},"obj":"32317402"},{"id":"32759645-32317402-58096257","span":{"begin":2561,"end":2564},"obj":"32317402"}],"text":"However, kidney-transplant recipients appear to be at particularly high risk for critical COVID-19 illness because of both their chronic immunosuppression and coexisting conditions [130]. Recently, at Montefiore Medical Center, NY, 36 consecutive adult kidney-transplant recipients who were positive for COVID-19 were identified [131], and Columbia University Kidney transplant program enrolled 15 kidney transplant recipients who required hospitalization for confirmed COVID-19 infection [132]. Both reports described management, clinical course and outcomes of those patients living with a kidney transplant affected by COVID-19. Patients were predominantly men, and the median age was 55 years. The most common comorbidities were the following: hypertension, diabetes mellitus, history of smoking and heart disease. Almost all patients were receiving tacrolimus, prednisone and mycophenolate mofetil or mycophenolic acid. The patients reported symptom onset ranging from 1 day to nearly 3 weeks before admission. The most common initial symptom was fever, but also cough, dyspnea, malaise, diarrhea and myalgias. Over 50% of the patients had bilateral/multifocal opacities noted on initial chest x-ray radiographic. Laboratory findings were lymphopenia, thrombocytopenia, low CD3, CD4 and CD8 cell counts. As inflammatory markers, ferritin levels, C- reactive protein, procalcitonin and D-dimer were high. Patients who were in a stable condition without major respiratory symptoms were monitored at home. In another report, among 41 outpatient kidney transplant recipients with suspected or known COVID-19 infection, about one third required hospitalization by the end of their follow-up; there were no differences in demographics or medical comorbidities between those who were or were not admitted to the hospital. These patients therefore required close clinical monitoring to prevent their organ deterioration until symptoms’ resolution [133]. As reported by Montefiore Medical Center and Columbia University, almost half of the patients had AKI, although none had a kidney biopsy performed to determine the cause, and required intubation and mechanical ventilation between 0 and 9 days after admission. In particular, Columbia University’s report observed that 27% of their cases required intubation, a proportion that is similar for cases in New York City overall [132]. Among the patients who developed AKI, only 20% of patients required RRT. At a median follow-up of 21 days, the mortality rate was about 28% of the kidney-transplant recipients [131,132]. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin."}

PMC:7464116 / 66147-68825 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7464116 / 66147-68825 JSON TXT